Objective: To examine the responsiveness of primary care providers to pro-social and financial incentives to participate in a learning collaborative for the treatment of opioid use disorder (OUD).
Study Setting: We conducted a statewide experiment in North Carolina from January 2019 to November 2019 to expand access to support for providers learning to treat opioid use disorder using different types of messaging and incentives.
Study Design: We randomly assigned 15,835 primary care providers (physicians, nurse practitioners, and physician assistants) in North Carolina (NC) to receive one of four letters recruiting providers to participate in an online learning collaborative for providers learning to treat opioid use disorder. The four versions of the recruitment letters contained either pro-social messaging, mention of financial reimbursement for time spent in the learning collaborative, both, or neither.
Data Collection: We created a primary data source, tracking provider responses to the recruitment letters and emails.
Principal Findings: We found a 47.5% greater (p < 0.05) response rate using pro-social recruitment messaging that provided a greater description of the local conditions in each provider's region compared to the control group; this effect increased with higher overdose opioid death rates. Mention of financial reimbursement only modestly increased provider response rates. Some heterogeneity was observed by provider type, with NPs having the largest response to pro-social messaging.
Conclusions: Prosocial nudges had strong effects on efforts to enhance the behavioral health workforce in NC through participation in an ECHO for medication-assisted treatment (MAT) learning collaborative. The prosocial approach can and should be employed by states and professional societies in their efforts to create training programs for medication for OUD (MOUD), in order to expand access to lifesaving treatments for opioid use disorder.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928024 | PMC |
http://dx.doi.org/10.1111/1475-6773.13894 | DOI Listing |
Med Gas Res
January 2025
McLean Hospital, Harvard Medical School, Belmont, MA, USA.
Xenon gas is considered to be a safe anesthetic and imaging agent. Research on its other potentially beneficial effects suggests that xenon may have broad efficacy for treating health disorders. A number of reviews on xenon applications have been published, but none have focused on substance use disorders.
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine, Merit Health Wesley, Hattiesburg, USA.
Anterior cord syndrome is a rare yet critical neurological condition that poses significant challenges in clinical management. We present the case of a 71-year-old male with a medical history of hypertension, uncontrolled type II diabetes mellitus, hypothyroidism, and end-stage renal disease requiring dialysis who presented to the emergency department with complaints of chills, back pain, abdominal pain, and vomiting episodes. Based on the severity of the patient's illness, it was decided that inpatient admission would be best.
View Article and Find Full Text PDFAm J Psychiatry
January 2025
Department of Neuroscience, Medical University of South Carolina, Charleston (Kuhn, Crow, Walterhouse, Chalhoub, Dereschewitz, Roberts, Kalivas); School of Pharmacy, Center for Neuroscience, Pharmacology Unit, University of Camerino, Camerino, Italy (Cannella, Lunerti, Ciccocioppo); Interdisciplinary Ph.D. Program in Biostatistics (Gupta) and Department of Biomedical Informatics (Gupta, Allen, Chung), and Pelotonia Institute for Immuno-Oncology, James Comprehensive Cancer Center, Ohio State University, Columbus (Gupta, Allen, Chung); Department of Internal Medicine, Wake Forest University, Winston-Salem, NC (Cockerham, Beeson, Solberg Woods); Department of Psychology, Jacksonville State University, Jacksonville, AL (Nall); Institute for Genomic Medicine, University of California San Diego, La Jolla (Palmer); School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland (Hardiman).
Objective: The behavioral and diagnostic heterogeneity within the opioid use disorder (OUD) diagnosis is not readily captured in current animal models, limiting the translational relevance of the mechanistic research that is conducted in experimental animals. The authors hypothesized that a nonlinear clustering of OUD-like behavioral traits would capture population heterogeneity and yield subpopulations of OUD vulnerable rats with distinct behavioral and neurocircuit profiles.
Methods: Over 900 male and female heterogeneous stock rats, a line capturing genetic and behavioral heterogeneity present in humans, were assessed for several measures of heroin use and rewarded and non-rewarded seeking behaviors.
Am J Psychiatry
January 2025
Biobehavioral Imaging and Molecular Neuropsychopharmacology Section, NIDA, Baltimore (Levinstein, Budinich, Michaelides); Department of Pathology and Experimental Therapeutics, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat, Barcelona (Bonaventura); Neuropharmacology and Pain Group, Neuroscience Program, IDIBELL-Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona (Bonaventura); Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (Schatzberg); Experimental Therapeutics and Pathophysiology Branch, NIMH, Bethesda (Zarate); Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (Michaelides).
Ketamine is a racemic compound and medication comprised of ()-ketamine and ()-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such as anxiety, obsessive-compulsive, and opioid use disorders.
View Article and Find Full Text PDFJ Psychoactive Drugs
January 2025
McGaw Medical Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Co-occurring substance use disorders are common in medical settings, yet limited literature exists on concomitant pharmacological management. We present a case where low-dose buprenorphine induction (LDBI) and rapid phenobarbital taper were performed concurrently in a hospital setting to manage co-occurring opioid dependence (on chronic methadone maintenance therapy) and benzodiazepine dependence (prescribed alprazolam). The simultaneous management was well-tolerated and completed with minimal complications, successfully enabling candidacy for the patient's preferred disposition.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!